Nizhny Novgorod

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Bladder cancer4 trials
• Asthma3 trials
• Chronic lymphocytic leukaemia3 trials
• Amyloidosis2 trials
• COPD2 trials
• Heart failure2 trials
• Metastatic breast cancer2 trials
• Prostate cancer2 trials
• Chronic kidney disease1 trial
• Gastric and oesophageal cancer1 trial
• High blood pressure1 trial
• and 5 more

Phase

• Phase 311 trials
• Phase 24 trials

Status

• Active, not recruiting16 trials
• Completed10 trials
• Recruiting4 trials
• Terminated3 trials
• Suspended1 trial

Lead sponsor

• AstraZeneca31 trials
• Checkpoint Therapeutics, Inc.1 trial
• MedImmune LLC1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial

Running trials

• Active, not recruiting

  A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

  NCT07143604· Phase 2· AstraZeneca· Source

• Recruiting

  Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

  NCT07052578· AstraZeneca· Source

• Recruiting

  TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

• Recruiting

  Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

  NCT07088991· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

  NCT06606847· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

  NCT06521229· AstraZeneca· Source

• Recruiting

  Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

  NCT06472310· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

  NCT05941897· Phase 2· AstraZeneca· Source

• Active, not recruiting

  CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

  NCT05887011· AstraZeneca· Source

• Active, not recruiting

  A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

  NCT05456867· AstraZeneca· Source

• Active, not recruiting

  CLL Therapy Approaches in Russia

  NCT05140369· AstraZeneca· Source

• Active, not recruiting

  A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

  NCT04351555· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

  NCT03528694· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· Phase 2· MedImmune LLC· Source

• Active, not recruiting

  Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

  NCT00099437· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Bladder cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Study of Patient With Frequent COPD Exacerbations

  NCT07221981· AstraZeneca· Source

• Completed

  Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia

  NCT06566885· AstraZeneca· Source

• Completed

  PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia

  NCT06372431· AstraZeneca· Source

• Completed

  MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA

  NCT06422676· AstraZeneca· Source

• Completed

  Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia

  NCT06414746· AstraZeneca· Source

• Terminated

  Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  NCT06338839· AstraZeneca· Source

• Completed

  The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)

  NCT06056778· AstraZeneca· Source

• Completed

  HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

  NCT05913440· AstraZeneca· Source

• Terminated

  Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

  NCT04786964· Phase 3· Checkpoint Therapeutics, Inc.· Source

• Completed

  ALICIA (Acalabrutinib in CLL Therapy)

  NCT04746950· AstraZeneca· Source

• Completed

  Heart Failure Patients Registry

  NCT04709263· AstraZeneca· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· Phase 3· AstraZeneca· Source